Publications

  1. Ruff M, Kizilbash S, Buckner J. Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. Expert Rev Anticancer Ther. 2020 May; 20 (5):355-363 Epub 2020 May 12
    View PubMed
  2. Kerezoudis P, Goyal A, Lu VM, Alvi MA, Bydon M, Kizilbash SH, Burns TC. The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the National Cancer Database. J Neurooncol. 2020 Jan; 146 (2):303-310 Epub 2019 Dec 24
    View PubMed
  3. Ruff MW, Kizilbash SH. Glioblastoma with bilateral extraocular muscle infiltration preceded by evidence of vascular tropism. J Clin Neurosci. 2019 Mar; 61:277-278 Epub 2018 Nov 22
    View PubMed
  4. Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharm Res. 2018 Jul 12; 35 (9):177 Epub 2018 July 12
    View PubMed
  5. Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018 Jan 22; 20 (2):184-191
    View PubMed
  6. Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Front Oncol. 2018; 8:670 Epub 2019 Jan 22
    View PubMed
  7. Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther. 2017 Dec; 16 (12):2735-2746 Epub 2017 Sept 25
    View PubMed
  8. Shin JY, Kizilbash SH, Robinson S, Uhm JH, Jatoi A. Incidence, Characteristics, and Implications of Seizures in Patients With Glioblastoma. Am J Hosp Palliat Care. 2017 Aug; 34 (7):650-653 Epub 2016 May 05
    View PubMed
  9. Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016 Aug; 97: (2)108-20.
    View PubMed
  10. Shin JY, Kizilbash SH, Robinson SI, Uhm JH, Hammack JE, Lachance DH, Buckner JC, Jatoi A. Seizures in patients with primary brain tumors: what is their psychosocial impact? J Neurooncol. 2016 Jun; 128 (2):285-91 Epub 2016 Mar 15
    View PubMed
  11. Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst. 2016 May; 108 (5) Epub 2015 Nov 27
    View PubMed
  12. Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther. 2015 Dec; 14 (12):2735-43 Epub 2015 Oct 05
    View PubMed
  13. Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, Laack NN, Parney IF, Uhm JH, Buckner JC. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. J Neurooncol. 2014 Oct; 120 (1):85-93 Epub 2014 July 04
    View PubMed
  14. Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res. 2014 Jul 15; 20 (14):3730-41 Epub 2014 May 16
    View PubMed
  15. Kizilbash SH, Ward KC, Liang JJ, Jaiyesimi I, Lipscomb J. Survival outcomes in patients with early stage, resected pancreatic cancer - A comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens. Int J Clin Pract. 2014; 68(5):578-89.
    View PubMed
  16. Liang JJ, Kizilbash SH, Haluska P. Intrathecal metastases causing conus medullaris syndrome. QJM. 2014 Jan; 107: (1)75.
    View PubMed
  17. Dhamija R, Nickels KC, Calero A, Doraiswamy B, Rosenberg J, Kizilbash SH, Kizilbash SJ, Agrawal R. Case 1: Foot deformities, asymmetric calf muscles, and frequent falls in an 8-year-old boy. Case 2: Seizures in a 5-month-old boy whose mother recently emigrated from Honduras. Case 3: A gradually increasing perianal mass in a teenage girl. Pediatr Rev. 2011 Apr; 32 (4):163-8
    View PubMed
  18. Agrawal V, Kizilbash S, McCullough P. New therapeutic agents for diabetic kidney disease Therapy. July 2008; 5(4):553-575.